Close menu




June 22nd, 2021 | 14:07 CEST

Steinhoff, Barsele Minerals, Bayer - This is explosive for the stock markets

  • Investments
Photo credits: pixabay.com

Will the central banks change their direction, or will "the policy of cheap money" remain in place with unlimited bond purchases and zero interest rates to benefit growth? Last week, the markets were already caught on the wrong foot after the FED forecast two interest rate hikes for 2023. Then, the President of the St. Louis Fed, James Bullard, added even more salt to investors' wounds. He sees an accelerated tightening of monetary policy as a normal reaction to economic growth and rampant inflation in the wake of the economy's return from the Corona shock.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: NL0011375019 , CA0688921083 , DE000BAY0017

Table of contents:


    Losses across the board

    Markets around the world fell sharply on fears of an earlier-than-expected turnaround in interest rates. The US Dow Jones and the market-wide S&P 500 indices posted their worst week since October of last year, and the Asian stock markets also fell, with a disproportionate drop of almost 4% yesterday. Already in the run-up to the FED meeting last Wednesday, the precious metals corrected sharply. If the gold followers were still hoping for a breakout above the striking resistance at USD 1,920, the positive picture from a technical perspective was negated with a sell-off to the USD 1,764 mark.

    From a technical perspective, this sharp correction makes it likely that the price of the precious yellow metal will once again test the double bottom formed in April at USD 1,680. However, in the long term, the fundamental facts, such as the escalating national debt, offer good anti-cyclical opportunities to participate in the rising gold price. In addition to an investment in bars or coins, stocks of gold mine operators in particular offer opportunities for above-average price gains.

    Pure gold in Europe

    If you ask investors about the best gold deposits in the world, the answer is South Africa, the USA or Australia. Hardly anyone has the Scandinavian countries on their radar. Yet Sweden is considered one of the safest and best gold sites globally because of its long mining history. About 500 km from the capital Stockholm, the Canadian exploration Company Barsele Minerals has a treasure in its hands with an exploration potential of no less than 3.5 million ounces of pure gold. The Barsele Project is nearly 47,000 hectares in size and is located in the Fennoscandian Shield that intersects the historically high-grade "Gold Line."

    Previously, Barsele Minerals held a 45% interest in the eponymous project, with the majority 55% held by industry giant Agnico Eagle, which has been the lead exploration program manager in recent years. Over the past six years, nearly 156,000 meters and 404 drill holes have been completed. Last month, a letter of intent was signed between the two parties whereby Barsele will acquire the 55% of Agnico Eagle by paying USD 45 million to become the sole owner. The exclusivity period runs until July 30, 2021, and can be extended for another 31 days under certain conditions. The transaction is to be financed through the issuance of a convertible bond. At the final closing, Barsele will also grant the contractual partner its own shares with a volume of 14.9% and 6 million warrants.

    Two years ago, an independent appraisal produced a resource estimate of 2.5 million ounces. A further 30,000 meters of drilling are now planned over the next two years. The target of the experienced management is 3.5 million ounces. Should the estimate only come close to being realized, the shares of Barsele Minerals have multiplication potential. Currently, the stock market value is around CAD 90 million. In addition, if the results continue to be positive, the project should be a potential takeover candidate for the major gold producers. Act counter-cyclically!

    Steinhoff subsidiary with results

    Steinhoff Investment Holdings, a subsidiary of Steinhoff International, reported an operating profit of ZAR 5.2 billion after material expenses in the six months to the end of March. This, compared with an operating loss of ZAR 10.6 billion a year earlier, after foreign exchange gains and a strong performance from Pepkor Holdings, supported the result. Sales from continuing operations increased 8% to ZAR 36.5 billion. Realized foreign exchange gains were ZAR 3.7 billion, compared with a loss of ZAR 4.8 billion in the same period last year.

    Provisions for the litigation settlement proposal were increased from ZAR 9.4 billion to ZAR 10.6 billion, resulting in an additional expense of ZAR 1.2 billion. A dividend of 292.43 cents per preferred share was also declared.

    Positive voices for Bayer

    According to analysts at Deutsche Bank, record prices for agricultural commodities should give Bayer AG's results some room to run. Thus, analyst Falko Friedrichs left the pharmaceutical giant's shares with a price target of EUR 66.

    Another positive was a study by the European Food Safety Authority (EFSA), which considers the controversial weedkiller glyphosate harmless and favors a renewed approval. Animal studies, epidemiological studies and statistical analyses have shown that the product is neither carcinogenic nor mutagenic and therefore poses no risk to consumers. The testing authorities reached this concordant assessment in France, the Netherlands, Sweden and Hungary, which EFSA had commissioned.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read